GADICKE ANSBERT — SEC insider filings
SEC reporting owner CIK 1134655. 87 insider filings on record with FilingPulse; latest filed 2026-09-09.
Transaction summary — filings shown
Covers the 50 most recent of 87 filings on record, filed 2021-06-30 to 2026-09-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 1,212,777 shares, $22,029,986 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 155 legs across 43 filings — 5,438,019 shares, $74,219,602 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 25.
- Largest priced transaction: purchase of 1,112,777 shares @ $18.00 ($20,029,986) in Aktis Oncology, Inc., filed 2026-01-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| iTeos Therapeutics, Inc. (ITOS) | — | 17 | — | 67 legs · 2,504,560 sh · $55,755,062 | 2 |
| Aktis Oncology, Inc. (AKTS) | 10% owner | 1 | 1 leg · 1,112,777 sh · $20,029,986 | — | 6 |
| Cullinan Oncology, Inc. (CGEM) | Director | 10 | — | 38 legs · 302,396 sh · $8,850,284 | 2 |
| Entrada Therapeutics, Inc. (TRDA) | 10% owner | 6 | 1 leg · 100,000 sh · $2,000,000 | 14 legs · 540,669 sh · $4,517,581 | 4 |
| Repare Therapeutics Inc. (RPTX) | 10% owner | 2 | — | 6 legs · 81,279 sh · $2,736,793 | — |
| Werewolf Therapeutics, Inc. (HOWL) | — | 10 | — | 29 legs · 1,938,945 sh · $2,227,963 | 3 |
| TCR2 THERAPEUTICS INC. (TCRR) | Director, 10% owner | 2 | — | 1 leg · 70,170 sh · $131,920 | 6 |
| Allovir, Inc. (ALVR) | Director, 10% owner | 2 | — | — | 2 |
Insider filings — GADICKE ANSBERT
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-09 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Sale (S): 38,500 @ $7.11 · Sale (S): 192,500 @ $7.41 · Sale (S): 28,837 @ $7.13 | EDGAR |
| 2026-09-03 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Sale (S): 29,088 @ $7.06 · Sale (S): 25,131 @ $7.19 · Sale (S): 32,263 @ $7.17 | EDGAR |
| 2026-08-31 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Sale (S): 38,922 @ $7.20 · Sale (S): 3,733 @ $7.01 · Sale (S): 44,259 @ $6.99 | EDGAR |
| 2026-08-26 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Sale (S): 21,623 @ $7.34 · Sale (S): 26,522 @ $7.54 · Sale (S): 14,569 @ $7.06 | EDGAR |
| 2026-01-14 | 4 | Aktis Oncology, Inc. (AKTS) jointly with MPM ASSET MANAGEMENT LLC, Oncology Impact Private Investment Fund 2, L.P. | Conversion (C): 1,314,262 · Conversion (C): 5,914,197 · Conversion (C): 1,577,119 · Purchase (P): 1,112,777 @ $18 · Conversion (C): 5,000,000 (derivative) @ $0 · Conversion (C): 22,500,000 (derivative) @ $0 · +1 more | EDGAR |
| 2025-12-04 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 59,277 @ $0.89 · Sale (S): 57,225 @ $0.87 · Sale (S): 83,230 @ $0.97 | EDGAR |
| 2025-12-01 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 60,733 @ $0.98 · Sale (S): 20,277 @ $0.99 · Sale (S): 60,917 @ $0.94 | EDGAR |
| 2025-11-25 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 64,331 @ $0.83 · Sale (S): 88,802 @ $0.98 · Sale (S): 42,533 @ $0.92 | EDGAR |
| 2025-11-20 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 52,627 @ $0.93 · Sale (S): 66,324 @ $0.94 · Sale (S): 41,152 @ $0.89 | EDGAR |
| 2025-11-17 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 90,951 @ $0.98 · Sale (S): 61,640 @ $0.93 · Sale (S): 57,061 @ $0.95 | EDGAR |
| 2025-11-12 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 68,480 @ $1.11 · Sale (S): 48,570 @ $1.18 · Sale (S): 55,810 @ $1.14 · Sale (S): 40,669 @ $1.09 | EDGAR |
| 2025-11-06 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 140,488 @ $1.22 · Sale (S): 47,950 @ $1.22 · Sale (S): 54,452 @ $1.21 | EDGAR |
| 2025-11-03 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 86,936 @ $1.43 · Sale (S): 114,044 @ $1.28 · Sale (S): 94,063 @ $1.29 | EDGAR |
| 2025-10-29 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 72,709 @ $1.72 · Sale (S): 69,068 @ $1.64 · Sale (S): 134,240 @ $1.55 | EDGAR |
| 2025-05-15 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with MPM BioImpact LLC, Oncology Impact Fund (Cayman) Management L.P., UBS Oncology Impact Fund L.P. | Sale (S): 1,031,931 @ $8.06 | EDGAR |
| 2025-04-30 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM Oncology Innovations Fund GP LLC, MPM ASSET MANAGEMENT LLC | Option exercise/expiry (X): 50,873 @ $0.09 · Sale (S): 4,386 @ $1.05 · Option exercise/expiry (X): 8,031 (derivative) @ $0 · Option exercise/expiry (X): 42,842 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, Foley Todd, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Sale (S): 22,935 @ $20.77 · Sale (S): 21,787 @ $20.23 | EDGAR |
| 2023-06-05 | 4 | TCR2 THERAPEUTICS INC. (TCRR) | Other (J): 304,001 @ $0 · Other (J): 3,854,963 @ $0 · Other (J): 3,370,982 @ $0 | EDGAR |
| 2023-05-24 | 4 | TCR2 THERAPEUTICS INC. (TCRR) | Option exercise/expiry (X): 178,269 @ $0.74 · Sale (S): 70,170 @ $1.88 · Option exercise/expiry (X): 42,761 (derivative) @ $0 · Option exercise/expiry (X): 135,508 (derivative) @ $0 | EDGAR |
| 2022-08-01 | 4 | Allovir, Inc. (ALVR) | Grant/award (A): 3,253,796 @ $4.61 | EDGAR |
| 2022-06-23 | 4 | Cullinan Oncology, Inc. (CGEM) | Grant/award (A): 16,475 (derivative) @ $0 | EDGAR |
| 2022-05-19 | 4 | Allovir, Inc. (ALVR) | Grant/award (A): 27,500 (derivative) @ $0 | EDGAR |
| 2022-03-25 | 4 | Cullinan Oncology, Inc. (CGEM) | Grant/award (A): 7,800 (derivative) @ $0 | EDGAR |
| 2022-01-06 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 158,579 @ $42.05 · Sale (S): 32,396 @ $43.20 · Sale (S): 11,318 @ $45.32 · Sale (S): 12,829 @ $46.47 · Sale (S): 30,347 @ $42.03 | EDGAR |
| 2021-12-07 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 29,402 @ $34.68 · Sale (S): 4,047 @ $35.44 · Sale (S): 300 @ $36.26 · Sale (S): 14,173 @ $32.35 · Sale (S): 1,960 @ $33.57 · Sale (S): 850 @ $34.08 · +3 more | EDGAR |
| 2021-12-02 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 9,809 @ $34.62 · Sale (S): 46,992 @ $35.19 · Sale (S): 10,111 @ $33.82 · Sale (S): 9,131 @ $34.61 · Sale (S): 1,500 @ $35.34 · Sale (S): 49,796 @ $33.74 · +1 more | EDGAR |
| 2021-11-30 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 10,952 @ $35.49 · Sale (S): 10,258 @ $36.03 · Sale (S): 16,856 @ $34.46 · Sale (S): 500 @ $35.37 | EDGAR |
| 2021-11-24 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Other (J): 15,671 @ $0 · Sale (S): 15,575 @ $37.16 · Sale (S): 19,758 @ $37.81 · Sale (S): 32,876 @ $36.21 · Sale (S): 600 @ $36.50 · Sale (S): 8,147 @ $35.20 · +2 more | EDGAR |
| 2021-11-04 | 4 | Entrada Therapeutics, Inc. (TRDA) jointly with MPM BioVentures 2014, L.P., EVNIN LUKE, MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM BIOVENTURES 2018 (B), L.P., MPM ASSET MANAGEMENT INVESTORS BV2018 LLC | Conversion (C): 3,816,760 · Conversion (C): 509,024 · Purchase (P): 100,000 @ $20 · Conversion (C): 27,617,675 (derivative) @ $0 · Conversion (C): 3,683,241 (derivative) @ $0 | EDGAR |
| 2021-10-18 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 14,882 @ $27.53 · Sale (S): 3,413 @ $28.01 · Sale (S): 10,320 @ $27.14 | EDGAR |
| 2021-10-14 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 14,260 @ $27.09 · Sale (S): 35,023 @ $27.13 · Sale (S): 45,719 @ $27.30 | EDGAR |
| 2021-10-12 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 1,922 @ $27 · Sale (S): 3,400 @ $27.01 · Sale (S): 81,684 @ $27.24 | EDGAR |
| 2021-10-05 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 11,471 @ $27 · Sale (S): 34,659 @ $27.06 | EDGAR |
| 2021-09-30 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 32,154 @ $27 · Sale (S): 3,836 @ $27 | EDGAR |
| 2021-09-27 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 60,600 @ $27.96 · Sale (S): 1,200 @ $28.38 · Sale (S): 8,221 @ $27.81 · Sale (S): 19,455 @ $27.09 | EDGAR |
| 2021-09-23 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 32,858 @ $27.47 · Sale (S): 23,921 @ $27.54 | EDGAR |
| 2021-09-20 | 4 | Cullinan Oncology, Inc. (CGEM) | Sale (S): 432 @ $29.06 · Sale (S): 3,124 @ $29.06 | EDGAR |
| 2021-09-20 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 35,565 @ $28.47 · Sale (S): 76,473 @ $28.82 · Sale (S): 17,743 @ $27.03 · Sale (S): 22,930 @ $27.84 | EDGAR |
| 2021-09-16 | 4 | Cullinan Oncology, Inc. (CGEM) | Sale (S): 982 @ $29.17 · Sale (S): 7,106 @ $29.17 · Sale (S): 888 @ $29.16 · Sale (S): 6,425 @ $29.16 | EDGAR |
| 2021-09-16 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 30,018 @ $27.50 · Sale (S): 6,063 @ $27.99 · Sale (S): 38,677 @ $27.79 · Sale (S): 1,659 @ $28.15 | EDGAR |
| 2021-09-13 | 4 | Cullinan Oncology, Inc. (CGEM) | Sale (S): 1,898 @ $29.35 · Sale (S): 13,727 @ $29.35 · Sale (S): 820 @ $29.04 · Sale (S): 5,931 @ $29.04 · Sale (S): 497 @ $29.10 · Sale (S): 3,595 @ $29.10 | EDGAR |
| 2021-09-13 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 38,028 @ $28.97 · Sale (S): 11,313 @ $27.86 · Sale (S): 11,330 @ $28.73 · Sale (S): 35,785 @ $27.64 | EDGAR |
| 2021-09-08 | 4 | Cullinan Oncology, Inc. (CGEM) | Sale (S): 1,760 @ $29.60 · Sale (S): 12,731 @ $29.60 · Sale (S): 3,465 @ $29.04 · Sale (S): 25,067 @ $29.04 · Sale (S): 1,499 @ $29.11 · Sale (S): 10,842 @ $29.11 | EDGAR |
| 2021-09-08 | 4 | iTeos Therapeutics, Inc. (ITOS) jointly with UBS Oncology Impact Fund L.P., BioImpact Capital LLC, Oncology Impact Fund (Cayman) Management L.P. | Sale (S): 50,996 @ $29.18 · Other (J): 31,340 @ $0 · Sale (S): 18,663 @ $28.61 · Sale (S): 1,573 @ $29.10 | EDGAR |
| 2021-09-02 | 4 | Cullinan Oncology, Inc. (CGEM) | Sale (S): 177 @ $29.43 · Sale (S): 1,285 @ $29.43 · Sale (S): 215 @ $30.14 · Sale (S): 1,553 @ $30.14 · Sale (S): 790 @ $29.47 · Sale (S): 5,714 @ $29.47 · +2 more | EDGAR |
| 2021-08-31 | 4 | Cullinan Oncology, Inc. (CGEM) | Sale (S): 1,846 @ $29.09 · Sale (S): 13,357 @ $29.09 · Sale (S): 4,285 @ $29.30 · Sale (S): 31,001 @ $29.30 | EDGAR |
| 2021-08-25 | 4 | Cullinan Oncology, Inc. (CGEM) | Sale (S): 7,376 @ $29.11 · Sale (S): 53,359 @ $29.11 · Sale (S): 7,025 @ $29.48 · Sale (S): 50,882 @ $29.48 · Sale (S): 237 @ $29.09 · Sale (S): 1,713 @ $29.09 | EDGAR |
| 2021-08-12 | 4 | Cullinan Oncology, Inc. (CGEM) | Sale (S): 347 @ $29.05 · Sale (S): 2,510 @ $29.05 | EDGAR |
| 2021-07-13 | 4 | Repare Therapeutics Inc. (RPTX) | Sale (S): 4,067 @ $33.06 · Sale (S): 57,301 @ $33.58 · Sale (S): 711 @ $34.10 | EDGAR |
| 2021-06-30 | 4 | Repare Therapeutics Inc. (RPTX) | Sale (S): 13,800 @ $34.06 · Sale (S): 2,700 @ $34.82 · Sale (S): 2,700 @ $33.29 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1134655 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs